公开(公告)号：EP1853583B1

公开(公告)日：2011-09-07

申请号：EP06735089.2

申请日：2006-02-14

申请人： Schering Corporation ,  Pharmacopeia, LLC

发明人： WONG, Michael K. C. ,  SHU, Youheng ,  YU, Wensheng ,  ROSENBLUM, Stuart B. ,  KOZLOWSKI, Joseph A. ,  MCGUINNESS, Brian F. ,  SHAO, Yuefei ,  HOBBS, Douglas W.

IPC分类号： C07D401/12 ,  C07D409/14 ,  C07D401/14 ,  C07D405/14 ,  C07D211/58 ,  C07D417/14 ,  C07D413/14 ,  A61K31/497 ,  A61P31/00 ,  A61P29/00

CPC分类号： C07D401/14 ,  C07D211/58 ,  C07D401/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14

摘要： The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: Chemical formual should be inserted here as it appears on the abstract in paper form. and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non limiting example(s) include, psoriasis), autoimmune diseases (non limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g , tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

公开(公告)号：EP1853583A1

公开(公告)日：2007-11-14

申请号：EP06735089.2

申请日：2006-02-14

申请人： Schering Corporation ,  PHARMACOPEIA, INC.

发明人： WONG, Michael K. C. ,  SHU, Youheng ,  YU, Wensheng ,  ROSENBLUM, Stuart B. ,  KOZLOWSKI, Joseph A. ,  MCGUINNESS, Brian F. ,  SHAO, Yuefei ,  HOBBS, Douglas, W.

IPC分类号： C07D401/12 ,  C07D409/14 ,  C07D401/14 ,  C07D405/14 ,  C07D211/58 ,  C07D417/14 ,  C07D413/14 ,  A61K31/497 ,  A61P31/00 ,  A61P29/00

CPC分类号： C07D401/14 ,  C07D211/58 ,  C07D401/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14

摘要： The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: Chemical formual should be inserted here as it appears on the abstract in paper form. and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non limiting example(s) include, psoriasis), autoimmune diseases (non limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g , tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

公开(公告)号：EP1444203A1

公开(公告)日：2004-08-11

申请号：EP02784433.1

申请日：2002-11-12

申请人： Schering Corporation

发明人： FRIARY, Richard, J. ,  KOZLOWSKI, Joseph, A. ,  SHANKAR, Bandarpalle, B. ,  WONG, Michael K. C. ,  ZHOU, Guowel ,  LAVEY, Brian J. ,  SHIH, Neng-Yang ,  TONG, Ling ,  CHEN, Lei ,  SHU, Youheng

IPC分类号： C07D209/04 ,  C07D213/89 ,  C07D307/34 ,  C07D333/34 ,  C07D413/12 ,  C07D213/62 ,  C07D409/12 ,  C07D239/10

CPC分类号： C07D401/12 ,  C07D211/26 ,  C07D211/96 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12

摘要： There are disclosed compounds of the formula (I), or a pharmaceutically acceptable salt of the compound, which exhibit anti-inflammatory and immunomodulatory activity. Also disclosed are pharmaceutical compositions containing said compounds.